As explained in a leaflet on Patients’ Safety and Nanomedicines, published by the EAASM, a petition has been launched, supported by the ERA-EDTA, to ask for more collaborative actions towards a new and robust regulatory framework for Nanomedicines and Nanosimilars in Europe.
|